It has been suggested that the combined evaluation of natriuretic peptides and CRP may yield incremental prognostic information in the risk stratification of patients with ACS [12,13], and their combined use has been shown to improve long-term risk prediction of mortality in patients with stable coronary heart disease (CHD) [14]. The gene discussed is CRP; the disease is coronary artery disorder.